2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS02348
    CDK1 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK1 Human Pre-designed siRNA Set A
    CDK1 Human Pre-designed siRNA Set A
  • HY-170942
    CDK9/PARP-IN-1
    		Inhibitor
    CDK9/PARP-IN-1 (compound 37) is a CDK9/PARP inhibitor. CDK9/PARP-IN-1 inhibits CDK9 and PARP1 with IC50s of 118 and 107 nM, respectively. CDK9/PARP-IN-1 exhibits broad-spectrum antiproliferative effects across multiple cancer cell lines.
    CDK9/PARP-IN-1
  • HY-173310
    CDK2-IN-44
    		Inhibitor
    CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer.
    CDK2-IN-44
  • HY-143380
    Cdc7-IN-9
    		Inhibitor
    Cdc7-IN-9 is a potent Cdc7 inhibitor and can be used for cancer research.
    Cdc7-IN-9
  • HY-161736
    ARN25499
    		Inhibitor
    ARN25499 (compound 15) is a CDC42 inhibitor. ARN25499 can be used in cancer-related research.
    ARN25499
  • HY-155038
    Antitumor agent-104
    		Inhibitor
    Antitumor agent-104 (Compound 9) is an antitumor agent by inhibiting DNA damage repair in tumors. Antitumor agent-104 inhibits PARP1 enzymatic activity and the PAR protein level. Antitumor agent-104 also inhibits the expression of CDK12.
    Antitumor agent-104
  • HY-149398
    PARP-1/2-IN-2
    		Inhibitor
    PARP-1/2-IN-2-IN-1 (Compound 12e) is a PARP1/2/CDK12 inhibitor (IC50: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor.
    PARP-1/2-IN-2
  • HY-147797
    EGFR/HER2/CDK9-IN-2
    		Inhibitor
    EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity.
    EGFR/HER2/CDK9-IN-2
  • HY-RS02368
    Cdk16 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cdk16 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk16 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk16 Rat Pre-designed siRNA Set A
    Cdk16 Rat Pre-designed siRNA Set A
  • HY-151580S
    CDK2-IN-14-d3
    		Inhibitor
    CDK2-IN-14-d3 is a potent and selective CDK2 inhibitor. CDK2-IN-14-d3 can be used in research of cancer[1].
    CDK2-IN-14-d<sub>3</sub>
  • HY-170979
    CDK9 ligand 3
    		Ligand
    CDK9 ligand 3 is the ligand for CDK9 and can be used for synthesis of PROTAC degrader PROTAC CDK9 degrader-11 (HY-170978).
    CDK9 ligand 3
  • HY-162416
    CDK7-IN-27
    		Inhibitor
    CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with Ki of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase.
    CDK7-IN-27
  • HY-146214
    CDK4/6-IN-13
    As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.
    CDK4/6-IN-13
  • HY-137432D
    Avotaciclib sulfate
    		Inhibitor
    Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer.
    Avotaciclib sulfate
  • HY-RS02357
    Cdk12 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk12 Mouse Pre-designed siRNA Set A
    Cdk12 Mouse Pre-designed siRNA Set A
  • HY-159535
    Fovinaciclibum
    		Inhibitor
    Fovinaciclibum (Fovinaciclib) is a cyclin dependent kinase inhibitor, with antineoplastic effect.
    Fovinaciclibum
  • HY-163374
    Cdc7-IN-20
    		Inhibitor
    Cdc7-IN-20 (EP-05) is an orally effective and selective Cdc7 inhibitor with IC50 and Ki values of 0.93 and 0.11 nM, respectively. Cdc7-IN-20 has antitumor activity.
    Cdc7-IN-20
  • HY-168333
    5-HT6 inverse agonist 1
    		Inhibitor
    5-HT6 inverse agonist 1 (Compound 33) is an antagonist for 5-HT6 receptor with a Ki of 23 nM and a Kb of 6.62 nM. 5-HT6 inverse agonist 1 inhibits the 5-HT6R mediated Cdk5 and mTOR signaling pathway. 5-HT6 inverse agonist 1 reduces tactile hypersensitivity in spinal nerve ligation (SNL)-induced rat model.
    5-HT6 inverse agonist 1
  • HY-115904
    FLT3/CDK4-IN-1
    		Inhibitor
    FLT3/CDK4-IN-1 is a potent, high selective and orally active FLT3/CDK4 dual inhibitor (IC50=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo.
    FLT3/CDK4-IN-1
  • HY-N7045R
    Isosilybin B (Standard)
    		Inhibitor
    Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer.
    Isosilybin B (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.